A股異動丨唯捷創芯盤初升超7% 機構指行業有望復甦帶動公司業績增長
格隆匯5月18日丨唯捷創芯(688153.SH)盤初升超7%,現報64.9元,暫成交1.18億元超升停全天成交額,總市值266億元。天風證券最新報吿指出,公司L-PAMiD有望加速放量,產品線多點開花收效顯著。該行指22年下行週期公司存貨管控得當,23年行業有望迎來複蘇帶動公司業績穩定增長。此外,公司5G產品佔比持續提升,高集成度射頻功率放大器模組領域實現零的突破,有望深度射頻前端國產替代的廣闊前景。維持公司“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.